title: Targeted maximum likelihood estimation of effect modification parameters in survival analysis.
abstract: The Cox proportional hazards model or its discrete time analogue, the logistic failure time model, posit highly restrictive parametric models and attempt to estimate parameters which are specific to the model proposed. These methods are typically implemented when assessing effect modification in survival analyses despite their flaws. The targeted maximum likelihood estimation (TMLE) methodology is more robust than the methods typically implemented and allows practitioners to estimate parameters that directly answer the question of interest. TMLE will be used in this paper to estimate two newly proposed parameters of interest that quantify effect modification in the time to event setting. These methods are then applied to the Tshepo study to assess if either gender or baseline CD4 level modify the effect of two cART therapies of interest, efavirenz (EFV) and nevirapine (NVP), on the progression of HIV. The results show that women tend to have more favorable outcomes using EFV while males tend to have more favorable outcomes with NVP. Furthermore, EFV tends to be favorable compared to NVP for individuals at high CD4 levels.
authors.affiliation: University of California, Berkeley, USA.
authors.forename: Ori M
authors.initials: OM
authors.lastname: Stitelman
authors.forename: C William
authors.initials: CW
authors.lastname: Wester
authors.forename: Victor
authors.initials: V
authors.lastname: De Gruttola
authors.forename: Mark J
authors.initials: MJ
authors.lastname: van der Laan
mesh_terms: D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use; D048588:Benzoxazines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D016013:Likelihood Functions; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use; D016016:Proportional Hazards Models; D012737:Sex Factors; D016019:Survival Analysis
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D019829:Nevirapine; C098320:efavirenz